Norwegian version of this page

MAMP - Study: Medication Adherence Measurement in Pregnancy for Antidepressants and Asthma Medication

The MAMP study is a multinational web-based survey that focuses on the use of antidepressants and asthma medications in pregnancy. The study's objective is to gain insight into women's adherence, attitudes, and experiences with these medications in relation to pregnancy. Pregnant women and mothers of babies who have used antidepressants or asthma medications in the year before and/or during pregnancy will be invited to participate in the survey. The study will be conducted in Norway, the Netherlands, and several other European countries.

About adherence

Adherence refers to the extent to which a person takes their medication as agreed with the doctor, including taking the medication at the specified time, at the correct dosage, and for the prescribed or intended duration. WHO estimates that approximately half of all individuals who take medication on a daily basis have poor adherence, meaning they do not use medications in accordance with the doctor's prescription.

Study Background

There is limited knowledge about adherence to antidepressants and asthma medication during pregnancy. One of the reasons for this is a lack of standard questions tailored specifically for pregnant women that can map adherence to these medication groups. There is also a need to understand better women's experiences and attitudes towards the use of medications during pregnancy.

Purpose of this study

The "MAMP Study" aims to investigate medication adherence among women who use or have used antidepressants or asthma medications during pregnancy. Using a questionnaire, the study will survey topics such as actual medication use, attitudes, experiences, well-being and demographics.

The study results will help researchers develop new tools to measure adherence levels and be helpful in clinical practice as a support tool during doctor-patient conversations about the use of antidepressants and asthma medications during pregnancy.

Participants

This study will be launched and available to eligible pregnant women and mothers of babies in multiple countries, including Norway, the Netherlands, Sweden, Denmark, Belgium, France, Ireland, Italy, Switzerland, Serbia, and Portugal.

Personal data and privacy

All personal information from the questionnaires will be collected and stored anonymously using «Nettskjema» or «Castor», IT solutions that can be used for anonymous surveys according to current guidelines for privacy in Norway and the EU. Collected anonymous data will be stored on a secure server within Norway and the EU. Access to registered information will only be available to study collaborators and used only for the purpose previously described.

Published Feb. 15, 2024 4:48 PM - Last modified Feb. 16, 2024 7:47 AM

Participants

  • Hedvig Marie Egeland Nordeng University of Oslo
  • Angela Lupattelli University of Oslo
  • Anne Gerd Granås University of Oslo
  • Milica Zugic University of Oslo
  • Jenny Dinh Nguyen University of Oslo
  • Badra Mohamed University of Oslo
  • Marleen van Gelder (Netherlands)
  • Michael Ceulemans (Belgium)
  • Mette Bliddal (Denmark)
  • Sofie Dyekær Egsgaard (Denmark)
  • Marin Benoit (France)
  • Fergal O'Shaughnessy (Ireland)
  • Cleary Brian (Ireland)
  • Joan Devin (Ireland)
  • Maria Teresa Herdeiro (Portugal)
  • Marina Odalovic (Serbia)
  • Alice Panchaud (Switzerland)
  • Karen Maes (Switzerland)
  • Coraline Gillard (Switzerland)
  • Ulrika Nörby (Sweden)
  • Karin Svensberg (Sweden)
Detailed list of participants